Study casts doubt on ketamine nasal sprays for depression

March 16, 2018, University of New South Wales
Study casts doubt on ketamine nasal sprays for depression
Professor Colleen Loo. Credit: University of New South Wales

Researchers from the Black Dog Institute and UNSW Sydney have questioned the efficacy and safety of intranasal ketamine for depression, with their pilot trial stopped early due to poor side effects in patients.

Nasal devices have been touted as a promising way to deliver ketamine to with treatment-resistant depression, with this application easier to use and less invasive than other clinical delivery methods such as injections.

Yet contrary to previous trials, this latest study reveals the unpredictable nature of intranasal ketamine tolerance from one person to the next. The results are published in Journal of Psychopharmacology.

"It's clear that the intranasal method of ketamine delivery is not as simple as it first seemed," said lead author UNSW Professor Colleen Loo, who is based at Black Dog Institute.

"Many factors are at play when it comes to nasal spray ketamine treatments. Absorption will vary between people and can fluctuate on any given day within an individual based on such things as mucous levels in the nose and the specific application technique used."

The pilot trial aimed to test the feasibility of repeated doses of ketamine through an intranasal device amongst 10 participants with severe depression, ahead of a larger randomised controlled trial.

Participants were first given extensive training in proper self-administration techniques before receiving either a course of eight ketamine treatments or an active control over a period of four weeks, under supervision at the study centre.

Following initial reactions to the nasal spray, the dosage was adjusted amongst study patients to include longer time intervals between sprays.

However, the pilot study was eventually suspended after testing with five participants due to unexpected problems with tolerability. Side effects included high blood pressure, psychotic-like effects and motor incoordination which left some participants unable to continue to self-administer the spray.

"Intranasal ketamine delivery is very potent as it bypasses metabolic pathways, and ketamine is rapidly absorbed into the bloodstream," said Professor Loo.

"But as our findings show, this can lead to problems with high peak levels of ketamine in some people causing problematic side effects.

"Other recent studies have questioned whether changes to ketamine's composition after being metabolised into derivative compounds may actually deliver useful therapeutic effects.

"It remains unclear whether ketamine nasal sprays can be safely relied upon as a treatment for patients with ."

An earlier world-first study led by Professor Loo last year showed the effectiveness of ketamine's antidepressant effects in elderly patients when delivered in repeated doses, which were adjusted on an individual basis and given by the subcutaneous method (injections under the skin).

"Our prior research has shown that altering the dose on an individual patient basis was important. However, we wanted to see if a simpler approach using a set dose of ketamine for all people and administered by nasal spray could work just as well in this latest pilot," said Professor Loo.

"More research is needed to identify the optimal level of ketamine dosage for each specific application method before nasal sprays can be considered a feasible treatment option."

Her team are now recruiting participants for the world's largest independent trial of to treat depression, to determine the safety and effects of repeated dosing using subcutaneous injections.

Explore further: World-first ketamine trial shows promise for geriatric depression

More information: Verònica Gálvez et al. Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial, Journal of Psychopharmacology (2018). DOI: 10.1177/0269881118760660

Related Stories

World-first ketamine trial shows promise for geriatric depression

July 24, 2017
Australian researchers have completed the world's first randomised control trial (RCT) assessing the efficacy and safety of ketamine as a treatment for depression in elderly patients.

Antidepressant response within hours? Experts weigh evidence on ketamine as fast-acting treatment for depression

February 22, 2018
Recent studies suggest that ketamine, a widely used anesthetic agent, could offer a wholly new approach to treating severe depression—producing an antidepressant response in hours rather than weeks. Two reviews of recent ...

Ketamine works for female rats, too

February 26, 2018
A first of its kind study in female rats finds that a single, low dose of ketamine promotes resilience to future adverse events as it does in male rats. Published in eNeuro, the research addresses a critical gap in understanding ...

Suicidal thoughts rapidly reduced with ketamine, finds study

December 14, 2017
Ketamine was significantly more effective than a commonly used sedative in reducing suicidal thoughts in depressed patients, according to researchers at Columbia University Medical Center (CUMC). They also found that ketamine's ...

Ketamine for depression encouraging, but questions remain around long-term use

July 27, 2017
A world-first systematic review into the safety of ketamine as a treatment for depression, published in the prestigious Lancet Psychiatry, shows the risks of long-term ketamine treatment remain unclear.

Antidepressant effects of ketamine

December 8, 2016
New preclinical evidence was put forward by investigators in a series of presentations at the recent meeting of the American College of Neuropsychopharmacology suggest that the a metabolite of ketamine can produce antidepressant-like ...

Recommended for you

Researchers discover abundant source for neuronal cells

December 13, 2018
USC researchers seeking a way to study genetic activity associated with psychiatric disorders have discovered an abundant source of human cells—the nose.

New genetic clues to early-onset form of dementia

December 13, 2018
Unlike the more common Alzheimer's disease, frontotemporal dementia tends to afflict young people. It accounts for an estimated 20 percent of all cases of early-onset dementia. Patients with the illness typically begin to ...

Video game players frequently exposed to graphic content may see world differently

December 13, 2018
People who frequently play violent video games are more immune to disturbing images than non-players, a UNSW-led study into the phenomenon of emotion-induced blindness has shown.

How teens deal with stress may affect their blood pressure, immune system

December 13, 2018
Most teens get stressed out by their families from time to time, but whether they bottle those emotions up or put a positive spin on things may affect certain processes in the body, including blood pressure and how immune ...

How bullying affects the brain

December 12, 2018
New research from King's College London identifies a possible mechanism that shows how bullying may influence the structure of the adolescent brain, suggesting the effects of constantly being bullied are more than just psychological.

Length of eye blinks might act as conversational cue

December 12, 2018
Blinking may feel like an unconscious activity, but new research by Paul Hömke and colleagues at the Max Planck Institute for Psycholinguistics, suggests that humans unknowingly perceive eye blinks as nonverbal cues when ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

mob58
not rated yet Mar 18, 2018
Simple solution: the compound is orally active!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.